Tempest Therapeutics (TPST) Declines -40% Over 30 Days Amid Delisting Concerns

Key Takeaways

• Tempest Therapeutics (TPST) shares fell roughly 40% over the trailing 30 days, sliding from about $0.64 to around $0.38.
• A Nasdaq minimum bid price notice issued in early November 2026, along with associated delisting risk, has weighed heavily on sentiment.
• The stock trades near its 52-week low and roughly 96% below its 52-week high of about $9.75.
• Dilution risk, a constrained cash runway, and an ongoing strategic review remain central concerns for shareholders.
• As a clinical-stage biotech, Tempest generates no product revenue and depends on advancing its lead candidate, amezalpat (TPST-1120), in liver cancer.
• For additional context, review Tempest's Price Targets, Earnings, and Forecast pages to dig deeper into analyst expectations and outlook.
• Explore Trending AI Robots to see which AI trading strategies are currently active on this ticker.

Tempest Therapeutics (TPST): Company Background

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Brisbane, California, focused on developing small-molecule therapeutics for cancer. Its lead program is amezalpat (TPST-1120), an oral, selective PPAR-alpha antagonist being studied in combination with Roche's Tecentriq (atezolizumab) and Avastin (bevacizumab) for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

Randomized Phase 2 data showed a roughly six-month improvement in median overall survival for the amezalpat combination versus standard of care alone, and the U.S. Food and Drug Administration has granted amezalpat both Fast Track and Orphan Drug designations for HCC. The company's second clinical program, TPST-1495, is an EP2/EP4 dual antagonist with Orphan Drug designation for familial adenomatous polyposis (FAP). Because Tempest has no approved products or commercial revenue, investors track the stock primarily on clinical milestones, regulatory progress, and its ability to secure funding or a strategic partner. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the stock compares to others in the industry.

TPST Stock Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, TPST declined approximately 40%, falling from a closing price near $0.64 in mid-October to roughly $0.38 in mid-November. The move was broad-based rather than driven by a single-day event, with shares grinding lower through most of the period and setting fresh lows along the way.

The quarterly trend has been even more pronounced. From a level near $1.00 in mid-August, the stock has dropped roughly 60%, punctuated by a brief, high-volume intraday surge in mid-September that was fully retraced within weeks. The shares now sit close to their 52-week low and roughly 96% below their 52-week high, underscoring the depth of the multi-month downtrend.

What Drove the Recent 30-Day Decline

The most significant catalyst in the period was a Nasdaq notification received in early November 2026. The exchange determined that Tempest had failed to maintain a minimum closing bid price of $1.00 for 30 consecutive trading days, requiring the company to regain compliance by early May 2027 or face delisting. The deficiency notice crystallized the market's concerns about the company's financial position and triggered renewed selling pressure.

Alongside the delisting overhang, several structural factors weighed on the stock. Tempest has been pursuing financing through an at-the-market program, shelf registrations, and resale prospectuses, creating a persistent dilution overhang for a stock with a market capitalization of only a few million dollars. A thin cash runway, a going-concern designation, and the lack of a definitive strategic partnership or acquisition to fund a pivotal Phase 3 trial all reinforced the negative sentiment. With no product revenue and limited near-term clinical catalysts, buyers remained scarce through the period.

Drivers of the Quarterly Performance

The quarterly decline reflects a longer-running repricing of Tempest's risk profile. Since announcing in 2025 that it was exploring strategic alternatives, including partnerships, licensing, and mergers or acquisitions, the company has faced ongoing uncertainty about how the expensive Phase 3 development of amezalpat would be funded. Management has cited difficult capital markets for development-stage biotechs, and the company's cash position has continued to shrink against a sustained operating burn.

Broader pressures in the micro-cap biotech space have compounded the company-specific challenges. Rising rates of equity issuance, reverse-split history, and reduced institutional sponsorship have left the stock vulnerable to sustained selling. The move toward the Nasdaq minimum bid threshold, and the eventual breach of that threshold, converted those structural headwinds into an explicit listing-compliance risk that dominated the quarter's final weeks.

Key Factors to Watch Going Forward

Looking ahead, the central question for TPST is whether the company can restore Nasdaq compliance and secure the capital needed to advance amezalpat. Investors should monitor any announcements on reverse-stock-split plans, equity or debt financings, and progress toward a strategic partnership, licensing deal, or acquisition. Updates on the pivotal Phase 3 trial design and enrollment, as well as any new clinical data, will be key catalysts.

Regulatory milestones, including interactions with the FDA, and macroeconomic conditions affecting small-cap biotech financing will also influence the stock's trajectory. Given the company's limited cash runway and the absence of product revenue, the ability to execute a funding or strategic transaction is likely to remain the dominant driver of shareholder value in the near term. From what I see, this is important because it directly ties to the company's ability to continue operations.

Using AI Tools in My Research Process

In my analysis, I often turn to Tickeron’s platform for additional perspective on market patterns and automated strategies. One area I find useful is the AI Trading Bots section, which lets users review active algorithmic approaches across various tickers and timeframes. This helps provide context on how systematic strategies are responding to names like TPST without replacing traditional fundamental review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Dem Sem|Expert

Notable companies

Industry description

Market Cap

High and low price notable news

Volume